Communiqués Replimune Group, Inc.

Actions

REPL

US76029N1063

Temps réel estimé Cboe BZX Autres places de cotation 21:47:26 28/06/2024			Varia. 5j.	Varia. 1 janv.
8,895 ^USD	+4,40%		+4,71%	+5,58%

13/06	Replimune Group signe un accord de PIPE de 100 millions de dollars avec des investisseurs institutionnels	MT
07/06	REPLIMUNE GROUP, INC. : HC Wainwright réitère son opinion positive sur le titre	ZM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Replimune Announces $100 Million Private Placement Financing	13/06	AQ
Replimune : Corporate Presentation June 2024	12/06	PU
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	07/06	AQ
Replimune : Primary Analysis of the IGNYTE Registrational Cohort Presentation June 2024	06/06	PU
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma	06/06	AQ
Replimune : IGNYTE Oral Presentation at ASCO 2024	03/06	PU
Replimune : RP2 Uveal Melanoma Oral Presentation at ASCO 2024	03/06	PU
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	03/06	AQ
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05	AQ
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update	16/05	AQ
Replimune : Corporate Presentation May 2024	07/05	PU
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting	07/04	AQ
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04	AQ
Replimune : Uveal Melanoma Biomarker Poster at AACR 2024	01/04	PU
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions	26/03	AQ
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024	06/03	AQ
Replimune to Present at Three Upcoming Investor Conferences	05/03	AQ
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update	08/02	AQ
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference	28/12	AQ
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers	05/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Replimune Group, Inc.

Actions

REPL

US76029N1063

Communiqués

Filtres